Predicting Treatment Response of Multiple Myeloma Patients
Using Tumor Specific cell-free DNA

a 2019

Predicting Treatment Response of Multiple Myeloma Patients Using Tumor Specific cell-free DNA

GREGOROVÁ, Jana, Dávid VRÁBEL, Martina ALMÁŠI, Renata BEZDĚKOVÁ, Martin ŠTORK et. al.

Základní údaje

Originální název

Predicting Treatment Response of Multiple Myeloma Patients Using Tumor Specific cell-free DNA

Autoři

GREGOROVÁ, Jana (203 Česká republika, garant, domácí), Dávid VRÁBEL (703 Slovensko, domácí), Martina ALMÁŠI (203 Česká republika), Renata BEZDĚKOVÁ (203 Česká republika), Martin ŠTORK (203 Česká republika), Luděk POUR (203 Česká republika), Roman HAJEK (203 Česká republika) a Sabina ŠEVČÍKOVÁ (203 Česká republika, domácí)

Vydání

17th International Myeloma Workshop, 2019

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.298

Kód RIV

RIV/00216224:14110/19:00108624

Organizační jednotka

Lékařská fakulta

ISSN

DOI

http://dx.doi.org/10.1016/j.clml.2019.09.297

UT WoS

000491229800300

Klíčová slova anglicky

cell-free DNA; Liquid biopsy; Minimal residual disease

Štítky

rivok

Příznaky

Mezinárodní význam

Změněno: 14. 4. 2020 10:06, Mgr. Tereza Miškechová

Anotace

V originále

Great progress achieved in treatment of multiple myeloma (MM) over the past decade changed overall perception of importance of minimal residual disease (MRD) assessment. Since new drugs induce deep responses, MRD must be evaluated using sensitive techniques, such as allele specific PCR (ASO-PCR), next-generation sequencing (NGS) or flow cytometry. MM is a genetically heterogeneous disease characterized by multiple focal lesions in the bone marrow (BM). BM samples are typically used for analysis, but currently an alternative approach called liquid biopsies, which utilize body fluids for analysis of various molecules and cells, is intensively studied. Cell-free DNA as one type of the molecule which can be analyzed using liquid biopsy approach. In our study, patient-specific, clonotypic rearrangement of immunoglobulin heavy chain (IgH) gene, identified in BM samples, was used for qPCR analysis of cfDNA samples from peripheral blood. We demonstrate that dynamics and quantity of patient-specific, clonotypic IgH rearrangement found in cfDNA can predict the outcomes and response of MM patients.

Návaznosti

NV17-29343A, projekt VaV

Název: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu

Citovat

GREGOROVÁ, Jana, Dávid VRÁBEL, Martina ALMÁŠI, Renata BEZDĚKOVÁ, Martin ŠTORK, Luděk POUR, Roman HAJEK a Sabina ŠEVČÍKOVÁ. Predicting Treatment Response of Multiple Myeloma Patients Using Tumor Specific cell-free DNA. In 17th International Myeloma Workshop. 2019. ISSN 2152-2650. Dostupné z: https://dx.doi.org/10.1016/j.clml.2019.09.297.

@proceedings{1644956,
   author = {Gregorová, Jana and Vrábel, Dávid and Almáši, Martina and Bezděková, Renata and Štork, Martin and Pour, Luděk and Hajek, Roman and Ševčíková, Sabina},
   booktitle = {17th International Myeloma Workshop},
   doi = {http://dx.doi.org/10.1016/j.clml.2019.09.297},
   keywords = {cell-free DNA; Liquid biopsy; Minimal residual disease},
   language = {eng},
   title = {Predicting Treatment Response of Multiple Myeloma Patients Using Tumor Specific cell-free DNA},
   url = {https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31684-2/fulltext},
   year = {2019}
}

TY  - CONF
ID  - 1644956
AU  - Gregorová, Jana - Vrábel, Dávid - Almáši, Martina - Bezděková, Renata - Štork, Martin - Pour, Luděk - Hajek, Roman - Ševčíková, Sabina
PY  - 2019
TI  - Predicting Treatment Response of Multiple Myeloma Patients Using Tumor Specific cell-free DNA
KW  - cell-free DNA
KW  - Liquid biopsy
KW  - Minimal residual disease
UR  - https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31684-2/fulltext
L2  - https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31684-2/fulltext
N2  - Great progress achieved in treatment of multiple myeloma (MM) over the past decade changed overall perception of importance of minimal residual disease (MRD) assessment. Since new drugs induce deep responses, MRD must be evaluated using sensitive techniques, such as allele specific PCR (ASO-PCR), next-generation sequencing (NGS) or flow cytometry. MM is a genetically heterogeneous disease characterized by multiple focal lesions in the bone marrow (BM). BM samples are typically used for analysis, but currently an alternative approach called liquid biopsies, which utilize body fluids for analysis of various molecules and cells, is intensively studied. Cell-free DNA as one type of the molecule which can be analyzed using liquid biopsy approach. In our study, patient-specific, clonotypic rearrangement of immunoglobulin heavy chain (IgH) gene, identified in BM samples, was used for qPCR analysis of cfDNA samples from peripheral blood. We demonstrate that dynamics and quantity of patient-specific, clonotypic IgH rearrangement found in cfDNA can predict the outcomes and response of MM patients.
ER  -

GREGOROVÁ, Jana, Dávid VRÁBEL, Martina ALMÁŠI, Renata BEZDĚKOVÁ, Martin ŠTORK, Luděk POUR, Roman HAJEK a Sabina ŠEVČÍKOVÁ. Predicting Treatment Response of Multiple Myeloma Patients Using Tumor Specific cell-free DNA. In \textit{17th International Myeloma Workshop}. 2019. ISSN~2152-2650. Dostupné z: https://dx.doi.org/10.1016/j.clml.2019.09.297.

Podrobný výpis o publikaci